Good morning :)
$
₹
Clene Inc.

Clene Inc.

CLNN

NASDAQ
Asset Logo

Clene Inc.

CLNN

NASDAQ
$3.921.20% (-0.04)
$
₹
$3.921.20% (-0.04)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Consumer Defensive

Packaged Foods

Micro Cap

With a market cap of $58.3M the stock is ranked 4989

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

7.83
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.3
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+711.08%

Earnings Growth

+5.37%

Rev. Growth

+24.7%

See Detailed Forecast

Company Profile

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 711.08% growth, versus a trailing 3-year CAGR of -20.09%.

2026
Current$3.97Baseline
Analyst Target - 1 year
Target$32.2+711.08%

All values in $

202220232024202520262027$11.53$19.50$27.46Target+711.08%
2026
Current$3.97Baseline
Analyst Target - 1 year
Target$32.2+711.08%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 24.70% growth, versus a trailing 3-year CAGR of -24.94%.

2025
Current$200Baseline
Forecast for Dec 2026
High$400+100%
Average$249.4+24.7%
Low$105-47.5%

All values in $ Thousand

202120222023202420252026723473654342200Low-47.5%Average+24.7%High+100%
2025
Current$200Baseline
Forecast for Dec 2026
High$400+100%
Average$249.4+24.7%
Low$105-47.5%

All values in $ Thousand

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.77Baseline
Forecast for Dec 2026
High$-2.46+11.15%
Average$-2.62+5.37%
Low$-2.78-0.41%

All values in $

202120222023202420252026-11.36-14.85-7.81-5.3-2.77Low-0.41%Average+5.37%High+11.15%
2025
Current$-2.77Baseline
Forecast for Dec 2026
High$-2.46+11.15%
Average$-2.62+5.37%
Low$-2.78-0.41%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

0
-9.2
0
-8
0
-13.4
0
3.9
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue0.090.080.090.080.020.010.070.010.090.05
Net Income-6.78-7.98-13.54-0.75-7.41-8.77-9.22-8.09-13.423.91
Net Profit Margin-7456.04%-9179.31%-14889.01%-927.16%-27477.77%-58513.33%-11981.81%-53939.99%-14915.55%6991.07%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
Consumer DefensivePackaged Foods

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Clene Inc. -7.83-
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CLNN with any stock or ETF
Compare CLNN with any stock or ETF
Comparing from
CLNN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Clene Inc. (CLNN) share price today is $3.92 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $4.07 and a day low of $3.83.

  2. Clene Inc. stock trades on NASDAQ under the ticker symbol CLNN.

  3. Clene Inc.'s market capitalization is $58.27M as of November 7, 2026 at 2:29 AM IST.

  4. Clene Inc.'s price-to-earnings (P/E) ratio is N/A as of November 6, 2026.

  5. Clene Inc.'s price-to-book (P/B) ratio is 7.83 as of November 6, 2026.

  6. Yes, You can buy Clene Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Clene Inc. shares in three steps: 1. Search Clene Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Clene Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Clene Inc. (CLNN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.5497 shares at the current price of $3.92.

Loading...